Which drug works best for deadly fungus? researchers dig into past records
NCT ID NCT07191756
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 150 people treated for mucormycosis, a rare but serious fungal infection. Researchers compare two drugs—amphotericin B and isavuconazole—to see which leads to better survival and fewer side effects. The goal is to help doctors choose the best treatment for future patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCORMYCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University
Nanning, Guangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
- Custom 3D-Printed titanium implants could rebuild faces after injury or surgery
- Cresemba under the microscope: Real-World safety check for fungal infections
- Tailoring antifungal doses for seniors: a precision approach
- COVID-19's hidden toll: fungal infections rise in transplant patients
- Real-World study examines Isavuconazole's effectiveness against deadly fungal infections